Weil Company Inc. Has $2.34 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Weil Company Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,520 shares of the life sciences company’s stock after selling 3,624 shares during the quarter. Weil Company Inc.’s holdings in Illumina were worth $2,341,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Illumina in the 4th quarter valued at about $32,000. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. TD Private Client Wealth LLC grew its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. V Square Quantitative Management LLC increased its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its stake in shares of Illumina by 73.5% during the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after purchasing an additional 186 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Shares of Illumina stock opened at $95.73 on Wednesday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $15.16 billion, a PE ratio of -12.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. The company has a 50 day moving average of $126.02 and a 200-day moving average of $133.80. Illumina, Inc. has a 1-year low of $91.92 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ILMN. Robert W. Baird raised their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $130.00 to $100.00 in a research report on Monday, February 10th. Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.